187 related articles for article (PubMed ID: 17681004)
21. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease.
Chatfield S
Curr Med Res Opin; 1999; 15(3):152-9. PubMed ID: 10621921
[TBL] [Abstract][Full Text] [Related]
22. [Using gaviscon preparation for relief of esophageal, extraesophageal syndromes and functional dyspepsia in elderly patients with GERD].
Onuchina EV; Brikova SI; Tsukanov VV
Eksp Klin Gastroenterol; 2010; (10):80-6. PubMed ID: 21434379
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of action, efficacy, and onset dynamics of a single dose of alginates in patients with heartburn and GERD].
Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
Eksp Klin Gastroenterol; 2009; (4):77-85. PubMed ID: 19960998
[TBL] [Abstract][Full Text] [Related]
24. [Alginate-raft preparations in the treatment of acid reflux and heartburn (literature review)].
Mandel KG; Deggi BP; Brodi DA; Jeykobi GI
Eksp Klin Gastroenterol; 2008; (4):64-77. PubMed ID: 19145905
[No Abstract] [Full Text] [Related]
25. Patterns of food and acid reflux in patients with low-grade oesophagitis--the role of an anti-reflux agent.
Washington N; Steele RJ; Jackson SJ; Washington C; Bush D
Aliment Pharmacol Ther; 1998 Jan; 12(1):53-8. PubMed ID: 9692701
[TBL] [Abstract][Full Text] [Related]
26. Sodium Alginate (Gaviscon®) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants.
Corvaglia L; Spizzichino M; Zama D; Aceti A; Mariani E; Legnani E; Faldella G
Early Hum Dev; 2011 Dec; 87(12):775-8. PubMed ID: 21696897
[TBL] [Abstract][Full Text] [Related]
27. A comparison of gastro-oesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either Liquid Gaviscon or Algicon Suspension.
Washington N; Greaves JL; Iftikhar SY
Aliment Pharmacol Ther; 1992 Oct; 6(5):579-88. PubMed ID: 1420749
[TBL] [Abstract][Full Text] [Related]
28. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy.
Lindow SW; Regnéll P; Sykes J; Little S
Int J Clin Pract; 2003 Apr; 57(3):175-9. PubMed ID: 12723718
[TBL] [Abstract][Full Text] [Related]
29. [Estimation of efficiency of alginate-raft barrier in treatment of gastroesophageal reflux disease].
Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
Eksp Klin Gastroenterol; 2008; (6):77-81. PubMed ID: 19334430
[No Abstract] [Full Text] [Related]
30. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
[TBL] [Abstract][Full Text] [Related]
31. Effect of alginate in patients with GERD hiatal hernia matters.
Vardar R; Keskin M; Valitova E; Bayrakci B; Yildirim E; Bor S
Dis Esophagus; 2017 Oct; 30(10):1-7. PubMed ID: 28859383
[TBL] [Abstract][Full Text] [Related]
32. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
Mandel KG; Daggy BP; Brodie DA; Jacoby HI
Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
[TBL] [Abstract][Full Text] [Related]
33. [Restoration of the quality of life by eliminating and prevention of heartburn by alginate: results of multicenter study "VIA APIA"].
Lazebnik LB; Bordin DS; Masharova AA; Dzhulaĭ GS; Butov MA; Abdulkhakov RA; Eremina EIu; Tarasova LV; Safonova OV; Firsova LD; Kozhurina TS
Eksp Klin Gastroenterol; 2010; (6):70-6. PubMed ID: 20731169
[TBL] [Abstract][Full Text] [Related]
34. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes.
Dettmar PW; Sykes J; Little SL; Bryan J
Int J Clin Pract; 2006 Mar; 60(3):275-83. PubMed ID: 16494641
[TBL] [Abstract][Full Text] [Related]
35. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
Reimer C; Lødrup AB; Smith G; Wilkinson J; Bytzer P
Aliment Pharmacol Ther; 2016 Apr; 43(8):899-909. PubMed ID: 26909885
[TBL] [Abstract][Full Text] [Related]
36. [Gastroesophageal reflux. Results of a multicenter study of 170 patients on the therapeutic value of the Gaviscon drinkable suspension].
Chevrel B
Med Chir Dig; 1980; 9(6):535-9. PubMed ID: 6259459
[No Abstract] [Full Text] [Related]
37. [Heartburn and regurgitation in pregnancy. Efficacy and innocuousness of treatment with Gaviscon suspension].
Uzan M; Uzan S; Sureau C; Richard-Berthe C
Rev Fr Gynecol Obstet; 1988; 83(7-9):569-72. PubMed ID: 2848305
[TBL] [Abstract][Full Text] [Related]
38. In-vivo anti-reflux and raft properties of alginates.
Lambert JR; Korman MG; Nicholson L; Chan JG
Aliment Pharmacol Ther; 1990 Dec; 4(6):615-22. PubMed ID: 2129648
[TBL] [Abstract][Full Text] [Related]
39. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children.
Buts JP; Barudi C; Otte JB
Eur J Pediatr; 1987 Mar; 146(2):156-8. PubMed ID: 3032640
[TBL] [Abstract][Full Text] [Related]
40. Treatment for resilient cough owing to laryngopharyngeal reflux with a combination of proton pump inhibitor and Gaviscon® Advance: how we do it.
Lieder A; Issing W
Clin Otolaryngol; 2011 Dec; 36(6):583-7. PubMed ID: 22212545
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
